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Hepatocellular carcinoma (HCC) develops through a multistage process, but the nature of
the molecular changes associated with the different steps, the very early ones in particular,
is largely unknown. Recently, dysregulation of the NRF2/KEAP1 pathway and mutations
of these genes have been observed in experimental and human tumors, suggesting their
possible role in cancer development. To assess whether Nrf2/Keap1 mutations are early or
late events in HCC development, we investigated their frequency in the rat Resistant
Hepatocyte model, consisting of the administration of diethylnitrosamine followed by a
brief exposure to 2-acetylaminofluorene. This model enables the dissection of all stages of
hepatocarcinogenesis. We found that Nrf2/Keap1 mutations were present in 71% of early
preneoplastic lesions and in 78.6% and 59.3% of early and advanced HCCs, respectively.
Mutations of Nrf2 were more frequent, missense, and located in the Nrf2-Keap1 binding
region. Mutations of Keap1 occurred at a much lower frequency in both preneoplastic
lesions and HCCs and were mutually exclusive with those of Nrf2. Functional in vitro
and in vivo studies showed that Nrf2 silencing inhibited the ability of tumorigenic rat
cells to grow in soft agar and to form tumors. Unlike Nrf2 mutations, those of Ctnnb1,
which are frequent in human HCC, were a later event as they appeared only in fully
advanced HCCs (18.5%). Conclusion: In the Resistant Hepatocyte model of hepatocarci-
nogenesis the onset of Nrf2 mutations is a very early event, likely essential for the clonal
expansion of preneoplastic hepatocytes to HCC, while Ctnnb1 mutations occur only at
very late stages. Moreover, functional experiments demonstrate that Nrf2 is an oncogene
critical for HCC progression and development. (HEPATOLOGY 2015;62:851-862)
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H
epatocellular carcinoma (HCC) is the third
most frequent cause of cancer-related deaths
worldwide.1 Unfortunately, our knowledge of
the genomic alterations implicated in HCC initiation
and progression is still fragmentary. Moreover, differ-
ent from other solid tumors, no driving genetic altera-
tion to which tumor cells are addicted and that can be
effectively targeted has ever been identified. In this sce-
nario, HCC is probably one of the tumor types where
a more complete understanding of the underlying
genetic alterations could have a major impact on the
development of new treatment strategies. Also known
as NFE2L2, NRF2 is of particular interest as conflict-
ing results have been reported concerning the role of
the NRF2/KEAP1 pathway in cancer development.2 It
is a master transcriptional activator of genes encoding
enzymes that protect cells from oxidative stress and
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xenobiotics by induction of transcriptional regulation of
several antioxidant enzymatic pathways and various drug
efflux pumps and members of the multidrug resistance
protein family.3 It is negatively regulated and targeted to
proteosomal degradation by KEAP1.4 It was reported in
several studies that either loss of NRF2-KEAP1 interac-
tion or point mutations in the KEAP1 or NRF2 gene
are often associated with primary tumors.3 As for human
HCC, two recent studies using whole-exome sequencing
have revealed mutations of either NRF2 (6.4%) or
KEAP1 (8%),5,6 suggesting that dysregulation of this
pathway may play a relevant role in a subset of human
HCCs. Dysregulation of the Nrf2/Keap1 pathway,
monitored through analysis of the expression profile of
HCC, has also been described in two mouse models
where tumors developed in the liver of transforming
growth factor-a–c-myc double knockout or in the liver
of mice subjected to treatment with diethylnitrosamine
plus phenobarbital.7,8 In both these studies, as well as in
humans, however, gene mutation and/or dysregulation
of the Nrf2/Keap1 pathway were investigated only at
the final biological endpoint, namely, HCC. This makes
it difficult to understand whether alteration of this path-
way is critical for HCC development or if it represents
one of the several molecular changes featured in HCC.
The same problem applies also to mutations in the
Ctnnb1 gene; in fact, while mutations of this gene are
frequent in human HCC,9 whether they are involved in
HCC initiation10 or take place only during HCC pro-
gression11 is still a matter of debate.
Recently, we have shown that the Nrf2/Keap1 path-
way is dysregulated in the very early steps of the carci-
nogenic process in rat liver.12 Therefore, this study
investigated whether, similar to the human situation,
mutations of Nrf2 and/or Keap1 could be responsible
for the alteration of this pathway. Using the same ani-
mal model, we also investigated the occurrence of
Ctnnb1 mutations in the different stages of hepatocar-
cinogenesis. The results demonstrate that (1) muta-
tions of Nrf2 are extremely frequent in rat HCC, (2)
they represent a very early event in the tumorigenic
process occurring in early preneoplastic stages, and (3)
mutations of Ctnnb1, a gene frequently mutated in
human HCC, occur only during the progression from
early to advanced HCC.
Materials and Methods
Resistant-Hepatocyte Model. Guidelines for the
Care and Use of Laboratory Animals were followed dur-
ing the investigation. All animal procedures were
approved by the Ethical Committee of the University of
Cagliari and the Italian Ministry of Health. Male Fischer
F-344 rats (100-125 g) were purchased from Charles
River (Milan, Italy). Animals were injected intraperito-
neally with diethylnitrosamine (DENA; Sigma, St.
Louis, MO) at a dose of 150 mg/kg body weight. After
a 2-week recovery period, rats were fed a diet containing
0.02% 2-acetylaminofluorene (Sigma) for 1 week, fol-
lowed by a two-thirds partial hepatectomy and by an
additional week of the 2-acetylaminofluorene diet. Ani-
mals were then returned to the basal diet and killed at
10 weeks (preneoplastic nodules), 10 months (early
HCCs [eHCCs]), or 14 months (advanced HCCs
[aHCCs]) after DENA (for a schematic representation
of the experimental protocol, see Supporting Fig. S1A).
Histologic classification of preneoplastic nodules as
eHCCs or aHCCs was performed as described13 and as
detailed in the Supporting Information. Lung metastases
were macroscopically identified in aHCC-bearing rats
and further analyzed by hematoxylin and eosin staining.
Immunohistochemistry. Frozen liver sections were
collected and fixed in 220C acetone for 20 minutes
at room temperature. Paraffin-embedded sections were
incubated overnight with the following antibodies:
anti–placental glutathione S-transferase (MBL, Nagoya,
Japan), anti–glutamine synthase (GS; Sigma-Aldrich),
anti-NQO1 (Abcam, Cambridge, MA), and anti-
NRF2 (Santa Cruz Biotechnology, Dallas, TX) and
detected by antirabbit HRP antibody and 3,30-diami-
nobenzidine (Dako Envision). Sections were counter-
stained with Harris hematoxylin.
Laser-Capture Microdissection. We microdis-
sected 38 early preneoplastic nodules, 14 eHCCs, and
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27 aHCCs. Serial frozen sections of rat livers (16 lm
thick) were attached to 2-lm RNase free polyethylene
naphthalate membrane slides (Leica, Wetzlar, Ger-
many). Microdissection (Leica, LMD6000) was fol-
lowed by hematoxylin and eosin staining.
Quantitative Reverse-Transcriptase Polymerase
Chain Reaction Analysis. We isolated RNA from
microdissected preneoplastic and neoplastic lesions
using MirVana (Ambion, Austin, TX), as reported.12
Retrotranscription was performed starting from 0.5 lg
RNA/sample using the High Capacity Kit (Applied
Biosystems, Carlsbad, CA). Gene expression was
assessed by quantitative reverse-transcriptase polymer-
ase chain reaction (qRT-PCR) using specific TaqMan
probes (Nqo1, Gclc, Gsta4, Gs, Nrf2, Gapdh, and b-
actin; Applied Biosystems) or Express Sybr Green
(Invitrogen, Paisley, UK) for Keap1 and b-actin. The
relative levels were determined using the DDCT
method.
Sequencing. Genomic DNA was extracted from
the same samples used for qRT-PCR analysis with
minor modifications (see Supporting Information). To
identify Nrf2 mutations, we analyzed 38 rat preneo-
plastic lesions, 14 eHCCs, and 27 aHCCs obtained
from five, three, and 14 rats, respectively (Supporting
Fig. S1B). Nine fragments corresponding to the five
exons of rat Nrf2 gene (annealing 66C-60C) were
amplified using a Touch-down PCR protocol. For
details of the amplification protocols, please see the
Supporting Information. All PCR products were
amplified with High-Fidelity Taq polymerase (Plati-
num Taq DNA Polymerase High Fidelity; Invitrogen),
purified (by exonuclease 1 and shrimp alkaline phos-
phatase), and sequenced by fluorescence-based Sanger’s
direct sequencing in an ABI 3130 DNA capillary
sequencer. The mutation nomenclature described in
this study is given according to the numbering of the
amino acids in the human protein sequence
(Ensembl).
Transient Transfection of HEK293T Cells. In a
5% CO2 atmosphere HEK293T cells (ATCC, Mana-
ssas, VA) were cultured in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum (Lonza, Basel,
Switzerland). For transient transfection, an NRF2 len-
tiviral construct (217EX-T3128-Lv157; GeneCopoeia,
Rockville, MD) and a KEAP1 encoding plasmid
(pCDNA3-T7-Keap1; AddGene, Cambridge, MA)
were used. The mutant forms of NRF2 (V32E and
E82G) were obtained using the QuikChange II XL
Site-Directed Mutagenesis Kit (Agilent Technologies).
Using the calcium phosphate technique, HEK293T
cells were transfected with 10 lg of NRF2 and
KEAP1 constructs. Extraction of RNA was performed
upon 48 hours using the miRNeasy Mini Kit (Qia-
gen). Expression of NQO1 was evaluated by qRT-
PCR as described above. Western blot analysis was
performed as described.12
Stable Transduction With Nrf2 Targeting Short
Hairpin RNA. Cells isolated from an HCC-bearing
rat (resistant-hepatocyte [R-H] cells),12 cultured in
Roswell Park Memorial Institute 10% fetal bovine
serum medium, were stably transduced with the
217CS-SH213J-LVRH1P lentiviral vector containing a
specific custom-designed Nrf2 targeting short hairpin
RNA (GeneCopoeia). Transduced cells were selected
by treatment with puromycin (1 lg/mL for 7 days;
Invitrogen). Anchorage-independent growth in soft
agar was performed, embedding 3000 cells/well in
0.5% agar (SeaPlaque) in a 24-well plate. At the end
of the experiment grown colonies were stained with
crystal violet and quantified by counting all visible
colonies.
Wild-type and stably Nrf2 silenced R-H cells
(1,000,000/rat) were injected subcutaneously in the
flank of F-344 syngeneic rats (n5 6 rats/group).
Tumor size was measured twice a week by caliper. Sub-
cutaneous tumor volume was calculated using the for-
mula 4/3p (D/2) (d/2) 2, where d is the minor tumor
axis and D is the major tumor axis. Rats were sacri-
ficed 28 days after injection, and tumors were excised.
Statistical Analysis. Data are expressed as mean-
6 standard deviation or mean6 standard error. Analy-
sis of significance was done by the Student t test and
by one-way analysis of variance using GraphPad soft-
ware (La Jolla, CA). P values were considered signifi-
cant at P< 0.05.
Results
Onset of Nrf2 and Keap1 Mutations Is an Early
Event in Hepatocarcinogenesis. The R-H model
allows us to dissect the several stages of the carcino-
genic process (Supporting Fig. S1A).14 To investigate
whether Nrf2/Keap1 mutations take place early in the
carcinogenic process and are therefore fundamental for
HCC progression, we microdissected preneoplastic
nodules arising 10 weeks after DENA initiation; these
lesions were identified by their positivity to the placen-
tal form of glutathione S-transferase.15 As published
works indicate that most Nrf2 mutations occur in
exon 2,16 we sequenced this exon in 38 preneoplastic
lesions and in eight age-matched control livers, using
Sanger fluorescence-based sequence analysis. Muta-
tional analysis showed that 25/38 (65.8%)
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preneoplastic lesions did exhibit Nrf2 mutations. All of
them were missense, the most frequent being at
codons 32 (8/25, V32E) and 77 (4/25, D77G) (Fig.
1A,B). Twenty-four of 25 Nrf2 mutations were located
in the Nrf2 regions coding for either the LxxQDxDLG
motif (spanning amino acids 17-32) or the DxETGE
motif (amino acids 77-82) (Fig. 1C).16 Both these
motifs, evolutionarily conserved, bind to the Kelch
domain in Keap1. Analysis of the predicted effects of
these changes (MUpro software, at http://www.ics.uci.
edu/baldig/mutation.html, PolyPhen-2, at http://
genetics.bwh.harvard.edu/pph2/) showed that all the
mutations profoundly impair the binding between
Keap1 and Nrf2 and should be considered as activat-
ing mutations (data not shown). Given the extremely
high frequency of Nrf2 mutations in early lesions, we
sequenced the remaining Nrf2 exons (exons 1, 3, 4,
5); but no further mutations were detected. Because
Keap1 mutations disrupting the interaction with Nrf2
have already been described in human HCCs,4 we also
sequenced Keap1 exons coding for the Kelch domain,
involved in the binding to Nrf2.17 Notably, Keap1
mutations were found in two samples lacking Nrf2
mutations (Fig. 1A). Sequencing of Keap1 exons not
involved in Nrf2 binding was also performed, but no
further mutations were found. Complementary DNA
sequencing of Nrf2 full-length transcripts confirmed
the presence of the same mutations (data not shown).
Analysis of age-matched control livers revealed no
Nrf2/Keap1 mutation. Thus, Nrf2/Keap1 mutations
represent very early events in the hepatocarcinogenic
process.
Nrf2/Keap1 Mutations Lead To Pathway Activa-
tion. To directly establish whether Nrf2 and Keap1
mutations result in increased Nrf2 transcriptional
activity, we analyzed the expression of three established
target genes.18 The results shown in Fig. 2A demon-
strate that all three examined genes (Nqo1, Gclc,
Fig. 1. Mutations in Nrf2/Keap1 in preneoplastic lesions. (A) Mutations in Nrf2 and Keap1 identified in 38 preneoplastic lesions. All PCR prod-
ucts were purified and sequenced by fluorescence-based Sanger’s direct sequencing in an ABI 3130 DNA capillary sequencer. *These two muta-
tions were identified in the same lesion. (B) Electropherogram showing the most frequent Nrf2 mutation. (C) Scheme illustrating the position of Nrf2
mutations. All mutations are located in the LxxDQxDLG and DxETGE motifs responsible for Keap1 binding. Amino acid changes are shown in red.
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Gsta4) were strongly up-regulated in mutated preneo-
plastic lesions compared to control liver or to nonmu-
tated preneoplastic nodules, suggesting that these are,
actually, activating mutations.
To further assess if the mutations observed in preneo-
plastic lesions are indeed activating mutations, transient
transfection of HEK293T cells with lentiviral vectors
containing either wild-type or mutated NRF2 comple-
mentary DNA (V32E and E82G) was performed (Sup-
porting Fig. S2A). The results showed a significantly
stronger activation of the NRF2 pathway (evaluated as
NQO1 transcription) in cells expressing the two ana-
lyzed mutated forms (Fig. 2B). Moreover, while cells
transduced with both wild-type NRF2 and KEAP1
expression vectors did not show any increase of NQO1
expression, a significant increase of this gene was
observed in cells expressing the two NRF2 mutants and
KEAP1 (Fig. 2C and Supporting Fig. S2B). These data
provide evidence that the NRF2 mutated forms are
indeed unable to interact with KEAP1 and thus sustain
the increased pathway activation.
Nrf2 Mutations Occur at High Frequency in
HCCs. Next, we investigated Nrf2 mutations in
eHCCs developed 10 months after DENA treatment.
The lesions were composed of well-differentiated cells
with minimal atypia, frequent fatty change, and
increased nuclear/cytoplasmic ratio; they were not
encapsulated and blended imperceptibly into adjacent
nontumorous parenchyma. Normal lobular architec-
ture was replaced by a compact pattern of thin trabec-
ulae, with occasional small pseudoglandular or acinar
structures (Supporting Fig. S3A). No lung metastases
were found in animals bearing eHCC. Advanced
HCCs developed 4 months later and were composed
of poorly differentiated cells, not resembling hepato-
cytes, arranged in thick trabeculae or pseudoglandular
patterns. Pleomorphism, including bizarre giant cells,
was frequently seen (Supporting Fig. S3B). Lung
metastases (Supporting Fig. S3C) were found in 50%
of the animals.
Eight of the 14 eHCCs (57.1%) showed missense
mutation of Nrf2; three were located at codon 32
(V32E) and one each at codons 23 (L23P), 27
(D27G), 30 (L30R), 77 (D77G), and 82 (E82G) (Fig.
3A). Mutations of Keap1 were also observed in three
eHCCs. Interestingly, Keap1 mutations, similar to
what was observed in early lesions, were mutually
exclusive with Nrf2 mutations (Fig. 3A).
Mutations in Nrf2 were present in 15/27 aHCCs
(55.6%) developed at 14 months after DENA.
Eleven mutations were located in the region coding
for the LxxQDxDLG motif, while four were in the
DxETGE motif. In particular, seven mutations were
located at codon 32 (V32E), three at codon 30
(two L30H, one L30P) and one each at codons 29
(D29G), 77 (D77G), 79 (E79G), 80 (T80A), and
82 (E82G) (Fig. 3A). Only one mutation (V581E)
of Keap1 was detected in an aHCC devoid of Nrf2
mutations. Therefore, mutation of Nrf2/Keap1
accounted for 59.3% of the examined aHCCs. Age-
Fig. 2. Mutations in Nrf2 lead to pathway activation. (A) Expression
levels of three Nrf2-target genes in Nrf2/Keap1 mutated or nonmu-
tated preneoplastic lesions. Messenger RNA levels of Nqo1, Gclc, and
Gsta4 were evaluated by qRT-PCR and normalized to age-matched
control livers. Glyceraldehyde 3-phosphate dehydrogenase was used
as endogenous control. Error bars represent standard deviation.
***P< 0.001, **P< 0.01, *P< 0.05. (B,C) Lentiviral vectors con-
taining wild-type or mutated Nrf2 complementary DNAs were trans-
fected alone (B) or in combination with a Keap1 expression vector (C)
in HEK293T cells with the calcium-phosphate technique. Expression of
Nqo1 was evaluated by qRT-PCR 48 hours after transfection and nor-
malized to mock transfected cells. Beta-actin was used as endogenous
control. Error bars represent standard deviation. ****P< 0.0001,
**P< 0.01. NRF2_V32E and NRF2_E82G are NRF2 mutated forms;
“Mock” indicates empty vector. Abbreviation: mRNA, messenger RNA;
NS, not significant.
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matched control livers showed no mutations of Nrf2
or Keap1.
When we investigated the activation of the Nrf2/
Keap1 pathway, we found a strong up-regulation of
Nqo1 in eHCCs and aHCCs compared to normal
liver (Fig. 3B). Interestingly, unlike preneoplastic
lesions, no significant difference in Nqo1 expression
was found in mutated versus nonmutated HCCs (Fig.
3C), suggesting that at late stages the Nrf2/Keap1
pathway no longer depends on the presence of activat-
ing mutations only but can be activated by other
mechanisms as well.12
The Nrf2/Keap1 Pathway Is Also Activated in
Lung Metastases. Finally, we also examined the
Nrf2/Keap1 pathway in lung metastases of rats sacri-
ficed 14 months after DENA administration. The
results showed the presence of multiple metastases in
50% of HCC-bearing rats (Supporting Fig. S3C).
Fig. 3. Mutations in Nrf2/Keap1
and pathway activation in eHCCs
and aHCCs. (A) Mutations in Nrf2
and Keap1 in 14 eHCCs and 27
aHCCs. All PCR products were puri-
fied and sequenced by
fluorescence-based Sanger’s direct
sequencing in an ABI 3130 DNA
capillary sequencer. *These two
mutations were identified in the
same lesion. (B) Expression levels
of the Nrf2-target gene Nqo1, eval-
uated in all the eHCCs and aHCCs.
(C) Expression levels of Nqo1, eval-
uated in Nrf2/Keap1 mutated or
nonmutated eHCCs and aHCCs.
Messenger RNA levels in Nqo1
were evaluated by qRT-PCR and
normalized to age-matched control
livers. Glyceraldehyde 3-phosphate
dehydrogenase was used as
endogenous control. Error bars rep-
resent standard deviation.
***P< 0.001, **P< 0.01,
*P< 0.05. Abbreviation: mRNA,
messenger RNA; NS, not
significant.
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Lung metastases examined in five animals displayed
strong and uniform cytoplasmic positivity for Nqo1
(Fig. 4A,B). Accordingly, the same metastases exhibited
both cytoplasmic and nuclear positivity for Nrf2 (Fig.
4C). These data show that activation of the Nrf2 path-
way persists up to the final stage of the carcinogenic
process.
Targeting Nrf2 Mutations Impairs Anchorage-
Independent Growth and Tumorigenic Ability of
HCC Cells. Because our results suggest a critical role
of Nrf2 in early onset and progression of HCC, to
directly establish its oncogenic role, we moved to in
vitro studies. Neoplastic hepatocytes were isolated by
collagenase perfusion from the liver of a rat with mul-
tiple HCCs generated by the R-H model (R-H
cells).12 In agreement with our in vivo data, R-H cells
bear a mutation of Nrf2 (D38G). To establish the bio-
logical effect of the modulation of Nrf2 levels in HCC
cells, we performed soft agar assays on Nrf2-silenced
cells (Supporting Fig. S4). As shown in Fig. 5A, while
R-H cells were able to grow in soft agar, Nrf2 silenc-
ing caused a significant inhibition of their anchorage-
independent growth ability. We then tested if Nrf2
inhibition could impact their tumorigenic ability as
well. Parental R-H cells were able to form tumors in
all animals (six out of six) within 28 days when subcu-
taneously grafted into syngeneic F-344 rats; on the
contrary, the tumorigenic ability of Nrf2-silenced cells
was completely inhibited (Fig. 5B,C). No tumors, in
fact, were observed up to 3 months after cell grafting
(data not shown). These experiments suggest that Nrf2
targeting can effectively interfere with HCC growth.
Mutations of Ctnnb1 Are a Very Late Event in
the R-H Model. Dysregulation of the Wnt/b-catenin
pathway and occurrence of activating mutations in
CTNNB1 are among the most frequent alterations in
human HCC (15%-33%).5,6,9 However, whether
CTNNB1 mutations occur at early stages of the carcino-
genic process is unclear. Therefore, we investigated
Ctnnb1 mutations in the same samples (38 preneoplastic
lesions, 14 eHCCs, and 27 aHCCs) analyzed for Nrf2/
Keap1. Interestingly, while five of 27 aHCCs (18.5%)
exhibited missense mutations in hot spots of exon 3
(codons 32, 33, and 37, corresponding to human
codons 31, 32, and 36), none of the 38 preneoplastic
lesions, nor the eHCCs, harbored Ctnnb1 mutations
(Fig. 6A). This indicates that mutations of this gene,
unlike Nrf2, are a very late event in the process of hepa-
tocarcinogenesis induced in this rat model. Evidence
that either mutation of Ctnnb1 or activation of the
Wnt/b-catenin pathway is not involved in the early
stages of hepatocarcinogenesis in this rat model is also
supported by the following: (1) GS, a b-catenin target
gene19 analyzed by both qRT-PCR and immunohisto-
chemistry, was not expressed in preneoplastic nodules
(Fig. 6B,C) and (2) GS expression was significantly
increased only in advanced HCCs carrying Ctnnb1
mutations (Fig. 6D). Interestingly, only those mutations
resulting in TGT and TAT nucleotide substitutions, i.e.,
cysteine and tyrosine, were associated with enhanced
expression of GS (Fig. 6D). The same mutations were
found to be activating mutations in previous works.20
The KRAS gene is one of the most frequently mutated
in human cancers.21 However, an extremely low fre-
quency of mutation of this gene has been reported in
human HCC.5,6 In agreement with these findings, no
mutations of Kras could be observed in 30 preneoplastic
nodules. Kras mutations were found only in 1/14
eHCCs and 1/27 aHCCs. Both these mutations were in
codon 12 (Fig. 6A).
Fig. 4. The Nrf2/Keap1 pathway is activated in lung metastases. (A) Representative photomicrograph of a lung displaying several HCC metas-
tases, immunostained for Nqo1 (310). (B) Higher magnification of the inset shown in (A). Ciliary cells and metastatic hepatocytes are intensely
positive for Nqo1 staining (320). (C) Serial section of the same area as in (B), immunostained for Nrf2 (320).
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Discussion
Hepatocellular carcinoma is among the most aggres-
sive and prevalent cancers worldwide.1,22 Despite an
enormous number of studies aimed at elucidating the
exact nature of the molecular events fundamental for
the development and progression of HCC, there is
only a rudimentary understanding of the genetic/epige-
netic events associated with the development of HCC.
Moreover, due to the multistage nature of HCC, the
molecular pathogenesis of this cancer cannot be prop-
erly understood without more information on the
molecular alterations characterizing its early develop-
ment. Unfortunately, knowledge about molecular
events in early-stage HCC development is hampered
by the clinical difficulty in the histomorphologic dis-
tinction between nonmalignant lesions and early
HCC. Therefore, experimental models can help to
identify genetic changes occurring at initial stages of
the hepatocarcinogenic process. However, only few
studies have investigated the presence of mutations in
early lesions in nontransgenic mouse models,11,23 and
no studies have been done in rats. In the present study
we used a rat model characterized by a cirrhosis-like
reaction limited to the very early stages of the carcino-
genic process, while cirrhosis/fibrosis, usually associated
with human HCCs, is no longer present at later stages
Fig. 5. Silencing of Nrf2 impairs anchorage-independent growth and tumorigenic ability of HCC cells. Resistant-hepatocyte cells were isolated
by collagenase perfusion from the liver of a rat with multiple HCCs.12 (A) The R-H cells were stably transduced with an Nrf2 short hairpin RNA
lentiviral vector and puromycin-selected. Anchorage-independent growth was performed, embedding 3000 cells/well in soft agar. Ten days later
grown colonies were stained with crystal violet (bottom panel) and quantified by counting all visible colonies (upper panel). (B) Lentivirus-
transduced R-H cells (1 3 106) were subcutaneously injected into the right posterior flanks of syngeneic male Fischer F-344 rats (n5 12). The
graph shows tumor size, evaluated twice weekly by caliper (triplicate measurements); approximate volume of the mass was calculated as indi-
cated in Materials and Methods. Error bars represent standard deviation. **P< 0.01. (C) Rats injected with Nrf2 silenced or not silenced R-H
cells, 28 days postinjection. Abbreviation: sh, short hairpin.
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of the process. Nevertheless, the molecular signature of
rat HCCs strikingly overlaps with that of human
HCCs characterized by poor prognosis.12,13
We identified Nrf2 mutations at an extremely high
frequency and established that they occur at very early
stages of the carcinogenic process. The NRF2/KEAP1
axis is an integrated redox-sensitive signaling system
that regulates 1%-10% of human genes.3 Notably, an
oncogenic role of NRF2 activation has recently been
proposed, based on the finding that its overexpression
and/or mutation takes place in many human cancers,
including HCC,5,24,25 and that cancers with high
Fig. 6. b-Catenin mutations are a late event in hepatocarcinogenesis. (A) Mutations in Ctnnb1 and Kras found in 14 eHCCs and 27 aHCCs.
All mutations identified in the Ctnnb1 gene are located in exon 3, whereas Kras mutations are located in exon 1 and are missense mutations.
(B) Expression of GS in 38 preneoplastic nodules was assessed by qRT-PCR and compared to age-matched control rat livers. The levels were
calculated as fold change compared to control liver. Glyceraldehyde 3-phosphate dehydrogenase was used as endogenous control. Error bars
represent the standard deviation of technical triplicates. ***P< 0.001. (C) Serial sections of preneoplastic nodules stained for the placental
form of glutathione S-transferase (GSTP) and GS (43). (D) Quantitative RT-PCR analysis of GS expression in 14-month HCCs with or without
Ctnnb1 mutations. The levels were calculated as fold change compared to age-matched control livers. Glyceraldehyde 3-phosphate dehydrogen-
ase was used as endogenous control. *P< 0.05.
HEPATOLOGY, Vol. 62, No. 3, 2015 ZAVATTARI, PERRA, ET AL. 859
NRF2 levels are associated with poor prognosis.26,27
However, as pointed out by Sporn and Liby, whether
NRF2 plays a pro- or an antitumorigenic role in pre-
malignant lesions or early malignancy is still unclear.2
Indeed, while, on the one hand, NRF2 can protect
normal cells from oxidative stress and DNA-damaging
electrophiles, on the other hand, it can confer cytopro-
tection against high endogenous levels of reactive oxy-
gen species, thus increasing survival and resistance to
chemotherapy of cancer cells.27 The results stemming
from our in vivo and in vitro studies prove that Nrf2
plays a tumorigenic role and that inhibition of Nrf2 is
sufficient to impair colony-forming ability and in vivo
growth of hepatocarcinoma cells. The finding that acti-
vating mutations of Nrf2 occur at very early stages of
the carcinogenic process suggests that activation of the
Nrf2/Keap1 pathway is mandatory for HCC progres-
sion and that its inhibition deeply affects the tumori-
genic capacity of HCC cells.
Several studies have shown that many oncogenic
pathways are involved in the modulation of metabo-
lism.28,29 In this context, it is interesting to note that
Nrf2, other than maintaining redox homeostasis in
quiescent cells, is able to redirect glucose metabolism
into anabolic pathways30; indeed, while increased Nrf2
expression shifts glucose distribution toward purine
nucleotide synthesis (through activation of the pentose
phosphate pathway), Nrf2 knockdown inhibits this
process.30 Even if the impact of Nrf2/Keap1 activation
on the hepatocyte pentose phosphate pathway is
unknown, it is conceivable that Nrf2-induced expres-
sion of this pathway may account (1) for the aggressive
proliferation of Nrf2-overexpressing cells, by providing
purines required for nucleic acid synthesis, and (2) for
increased survival due to its ability to generate antioxi-
dant species.
Most of the identified Nrf2 mutations were located
in the regions coding for either the LxxQDxDLG
motif or the DxETGE motif (Fig. 1C). Both these
motifs, evolutionarily conserved, bind to the Kelch
domain in Keap1.31,32 The highest affinity is located
in the ETGE motif4,16; however, the weaker Keap1-
binding DLG region has been shown to be more vul-
nerable to structural changes and fits into a role of the
“latch” for the Nrf2-repression gate in the stress
response.16 On this basis, it seems that although the
DLG motif has a lower affinity than the ETGE motif,
mutations in the former motif may dramatically alter
the Nrf2 transcriptional activity.
Interestingly, we observed that while Nrf2/Keap1
mutations result in a much higher increase of Nrf2-
target genes in mutated preneoplastic lesions compared
to nonmutated ones (Fig. 2A), the Nrf2/Keap1 path-
way is activated to a similar extent in mutated and
nonmutated HCCs. These results suggest that while
gene mutations confer an advantage to preneoplastic
hepatocytes, other events may be responsible for the
activation of this pathway. Notably, up-regulation of
the Keap1-targeting miR-200a was previously found in
HCCs generated by the R-H model.12
Our results in rat liver provide evidence that the
Nrf2/Keap1 pathway plays a tumorigenic role not only
in the progression but also in the onset of HCC.
Although in humans NRF2/KEAP1 mutations have
been identified in HCCs,5,6 they were not found in dys-
plastic cirrhotic macronodules, where TERT mutation
was the earliest identified event.33 However, regulation
of telomerase activity is different in humans and rodents.
In fact, while telomerase activity is usually undetectable
in adult human tissues, several organs of normal adult
rodents display substantial amounts of telomerase activ-
ity; in particular, in the liver telomerase is expressed at a
nearly constant level throughout life and decreases dur-
ing liver regeneration.34,35 Indeed, we did not observe
an increase of telomerase expression in any of the lesions
we examined (data not shown). This remarkable differ-
ence between animal species may reflect the different
regulation mechanisms of telomerase expression. As for
the Nrf2/Keap1 pathway, it is important to underline
that it can be activated also through mechanisms other
than mutations, such as dysregulation of microRNAs
targeting Keap1.12 We can speculate that in a tumor not
induced by chemicals, epigenetic alterations controlling
the Nrf2/Keap1 pathway are more likely involved rather
than mutations.
Because the R-H model is based on initial exposure
to a genotoxic agent, it is conceivable that DENA
might have induced Nrf2/Keap1 mutations in hepato-
cytes and that these mutations might provide an
advantage for their clonal expansion; however, it is also
possible that the promoting procedure based on the
cytostatic effect of 2-acetylaminofluorene on regenerat-
ing liver might select, among the hepatocytes carrying
different DENA-induced lesions, those displaying
Nrf2/Keap1 mutations. Many studies, in fact, have
recently highlighted the interplay between initiated/
tumor cells and the microenvironment that can select
the genetic alterations conferring the best clonogenic
ability in a specific environment.
In the present study, Cnntb1 mutations, among the
most frequent in human HCC, were found only at very
late stages (aHCC) of the tumorigenic process but not
in preneoplastic nodules or early HCCs. Evidence that
Cnntb1 mutations are late events in the tumorigenic
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process, and thus b-catenin is unlikely a driving force in
early HCC development, also came from a mouse
model of hepatocarcinogenesis11; moreover, our data
showing that Ctnnb1 mutations are a late event are in
agreement with other works that identified b-catenin
mutation only in tumors (adenomas and HCCs) and
not in cirrhotic nodules.23,33,36 Taken together, all these
findings indicate that b-catenin activating mutations are
not involved in the onset of HCC but that they occur in
already transformed cells and are probably implicated in
the final steps of cancer progression. Because the R-H
model reflects a histological and molecular signature
similar to that of KRT-19-positive human HCCs char-
acterized by poor prognosis,13 results stemming from
this model are potentially relevant for human hepatic
tumorigenesis. In turn, they also suggest that studies
aimed at analyzing not only genetic/epigenetic changes
in advanced tumors but the chronological order of
molecular changes starting from the very early steps of
the process are highly relevant for the identification of
new fundamental alterations.
In summary, the present study identifies Nrf2 as the
most frequently mutated gene in a rat model of
chemically induced hepatocarcinogenesis and provides
evidence for its mandatory activation in HCC devel-
opment. In view of the recent finding of NRF2 muta-
tions in a subset of human HCC,5 the possibility that
Nrf2 might represent a new targetable gene should be
actively pursued. This study also provides evidence
that Cnntb1 mutations are a very late event as they
are absent in preneoplastic hepatocytes and in
eHCCs.
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